Literature DB >> 12970456

Dynamics of subgenomic hepatitis C virus replicon RNA levels in Huh-7 cells after exposure to nucleoside antimetabolites.

Lieven J Stuyver1, Tamara R McBrayer, Phillip M Tharnish, Abdalla E A Hassan, Chung K Chu, Krzysztof W Pankiewicz, Kyochi A Watanabe, Raymond F Schinazi, Michael J Otto.   

Abstract

Treatment with antimetabolites results in chemically induced low nucleoside triphosphate pools and cell cycle arrest in exponentially growing cells. Since steady-state levels of hepatitis C virus (HCV) replicon RNA were shown to be dependent on exponential growth of Huh-7 cells, the effects of antimetabolites for several nucleoside biosynthesis pathways on cell growth and HCV RNA levels were investigated. A specific anti-HCV replicon effect was defined as (i). minimal interference with the exponential cell growth, (ii). minimal reduction in cellular host RNA levels, and (iii). reduction of the HCV RNA copy number per cell compared to that of the untreated control. While most antimetabolites caused a cytostatic effect on cell growth, only inhibitors of the de novo pyrimidine ribonucleoside biosynthesis mimicked observations seen in confluent replicon cells, i.e., cytostasis combined with a sharp decrease in replicon copy number per cell. These results suggest that high levels of CTP and UTP are critical parameters for maintaining the steady-state level replication of HCV replicon in Huh-7 cells.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12970456      PMCID: PMC228517          DOI: 10.1128/jvi.77.19.10689-10694.2003

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  31 in total

Review 1.  Mechanism of action of ribavirin in the combination treatment of chronic HCV infection.

Authors:  Johnson Y N Lau; Robert C Tam; T Jake Liang; Zhi Hong
Journal:  Hepatology       Date:  2002-05       Impact factor: 17.425

2.  Phase II study of pyrazofurin in advanced colorectal carcinoma.

Authors:  E T Creagan; J Rubin; C G Moertel; A J Schutt; M J O'connell; R G Hahn; R J Reitemeir; S Frytak
Journal:  Cancer Treat Rep       Date:  1977 May-Jun

3.  Phase II trial of pyrazofurin in advanced head and neck cancer.

Authors:  E Cheng; V Currie; R E Wittes
Journal:  Cancer Treat Rep       Date:  1979 Nov-Dec

4.  Human hepatic glyceraldehyde-3-phosphate dehydrogenase binds to the poly(U) tract of the 3' non-coding region of hepatitis C virus genomic RNA.

Authors:  Juraj Petrik; Hayley Parker; Graeme J M Alexander
Journal:  J Gen Virol       Date:  1999-12       Impact factor: 3.891

5.  Viral and cellular determinants of hepatitis C virus RNA replication in cell culture.

Authors:  Volker Lohmann; Sandra Hoffmann; Ulrike Herian; Francois Penin; Ralf Bartenschlager
Journal:  J Virol       Date:  2003-03       Impact factor: 5.103

Review 6.  Novel cell culture systems for the hepatitis C virus.

Authors:  R Bartenschlager; V Lohmann
Journal:  Antiviral Res       Date:  2001-10       Impact factor: 5.970

7.  Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line.

Authors:  V Lohmann; F Körner; J Koch; U Herian; L Theilmann; R Bartenschlager
Journal:  Science       Date:  1999-07-02       Impact factor: 47.728

8.  Broad-spectrum antiviral and cytocidal activity of cyclopentenylcytosine, a carbocyclic nucleoside targeted at CTP synthetase.

Authors:  E De Clercq; J Murase; V E Marquez
Journal:  Biochem Pharmacol       Date:  1991-06-15       Impact factor: 5.858

Review 9.  HCV RNA-dependent RNA polymerase as a target for antiviral development.

Authors:  Michelle P Walker; Zhi Hong
Journal:  Curr Opin Pharmacol       Date:  2002-10       Impact factor: 5.547

10.  Antiviral effect and virus-host interactions in response to alpha interferon, gamma interferon, poly(i)-poly(c), tumor necrosis factor alpha, and ribavirin in hepatitis C virus subgenomic replicons.

Authors:  Robert E Lanford; Bernadette Guerra; Helen Lee; Devron R Averett; Brad Pfeiffer; Deborah Chavez; Lena Notvall; Catherine Bigger
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

View more
  30 in total

1.  Genotype and subtype profiling of PSI-7977 as a nucleotide inhibitor of hepatitis C virus.

Authors:  Angela M Lam; Christine Espiritu; Shalini Bansal; Holly M Micolochick Steuer; Congrong Niu; Veronique Zennou; Meg Keilman; Yuao Zhu; Shuiyun Lan; Michael J Otto; Phillip A Furman
Journal:  Antimicrob Agents Chemother       Date:  2012-03-19       Impact factor: 5.191

2.  Hepatitis C virus nucleotide inhibitors PSI-352938 and PSI-353661 exhibit a novel mechanism of resistance requiring multiple mutations within replicon RNA.

Authors:  Angela M Lam; Christine Espiritu; Shalini Bansal; Holly M Micolochick Steuer; Veronique Zennou; Michael J Otto; Phillip A Furman
Journal:  J Virol       Date:  2011-09-28       Impact factor: 5.103

3.  Comparative in vitro anti-hepatitis C virus activities of a selected series of polymerase, protease, and helicase inhibitors.

Authors:  Jan Paeshuyse; Inge Vliegen; Lotte Coelmont; Pieter Leyssen; Oriana Tabarrini; Piet Herdewijn; Harald Mittendorfer; Johnny Easmon; Violetta Cecchetti; Ralf Bartenschlager; Gerhard Puerstinger; Johan Neyts
Journal:  Antimicrob Agents Chemother       Date:  2008-07-14       Impact factor: 5.191

4.  Preexisting drug-resistance mutations reveal unique barriers to resistance for distinct antivirals.

Authors:  Margaret Robinson; Yang Tian; William E Delaney; Andrew E Greenstein
Journal:  Proc Natl Acad Sci U S A       Date:  2011-06-06       Impact factor: 11.205

5.  Inhibition of hepatitis C virus replicon RNA synthesis by PSI-352938, a cyclic phosphate prodrug of β-D-2'-deoxy-2'-α-fluoro-2'-β-C-methylguanosine.

Authors:  Angela M Lam; Christine Espiritu; Eisuke Murakami; Veronique Zennou; Shalini Bansal; Holly M Micolochick Steuer; Congrong Niu; Meg Keilman; Haiying Bao; Nigel Bourne; Ronald L Veselenak; P Ganapati Reddy; Wonsuk Chang; Jinfa Du; Dhanapalan Nagarathnam; Michael J Sofia; Michael J Otto; Phillip A Furman
Journal:  Antimicrob Agents Chemother       Date:  2011-03-28       Impact factor: 5.191

6.  Mathematical modeling of subgenomic hepatitis C virus replication in Huh-7 cells.

Authors:  Harel Dahari; Ruy M Ribeiro; Charles M Rice; Alan S Perelson
Journal:  J Virol       Date:  2006-10-11       Impact factor: 5.103

7.  Class III phosphatidylinositol 4-kinase alpha and beta are novel host factor regulators of hepatitis C virus replication.

Authors:  Jason Borawski; Philip Troke; Xiaoling Puyang; Veronica Gibaja; Shanchaun Zhao; Craig Mickanin; Juliet Leighton-Davies; Christopher J Wilson; Vic Myer; Ivan Cornellataracido; Jeremy Baryza; John Tallarico; Gerard Joberty; Marcus Bantscheff; Markus Schirle; Tewis Bouwmeester; Joanna E Mathy; Kai Lin; Teresa Compton; Mark Labow; Brigitte Wiedmann; L Alex Gaither
Journal:  J Virol       Date:  2009-07-15       Impact factor: 5.103

8.  Inhibition of hepatitis C virus replication by arsenic trioxide.

Authors:  Der-Ren Hwang; Yuan-Chin Tsai; Jin-Ching Lee; Kuo-Kuei Huang; Ren-Kuo Lin; Chia-Hua Ho; Jeng-Min Chiou; Ying-Ting Lin; John T A Hsu; Chau-Ting Yeh
Journal:  Antimicrob Agents Chemother       Date:  2004-08       Impact factor: 5.191

9.  Proliferation of mouse liver stem/progenitor cells induced by plasma from patients with acute liver failure is modulated by P2Y2 receptor-mediated JNK activation.

Authors:  Ting Wang; Yasuhiro Takikawa; Asako Watanabe; Keisuke Kakisaka; Kanta Oikawa; Kanta Oigawa; Yasuhiro Miyamoto; Kazuyuki Suzuki
Journal:  J Gastroenterol       Date:  2013-12-22       Impact factor: 7.527

10.  Temporal proteome and lipidome profiles reveal hepatitis C virus-associated reprogramming of hepatocellular metabolism and bioenergetics.

Authors:  Deborah L Diamond; Andrew J Syder; Jon M Jacobs; Christina M Sorensen; Kathie-Anne Walters; Sean C Proll; Jason E McDermott; Marina A Gritsenko; Qibin Zhang; Rui Zhao; Thomas O Metz; David G Camp; Katrina M Waters; Richard D Smith; Charles M Rice; Michael G Katze
Journal:  PLoS Pathog       Date:  2010-01-08       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.